Increased expression of Fz5 receptor matched with a decrease in NeuN immunoreactivity at 16w. by Carlos González-Fernández (2794207)

Investigating the shared genetics of non-syndromic cleft lip/palate and facial morphology by Laurence J. Howe (5579186)

“…Across 5,804 individuals of European ancestry from two studies, we found strong evidence, using PRS, of genetic overlap between nsCL/P and philtrum width; a 1 S.D. increase in nsCL/P PRS was associated with a 0.10 mm decrease in philtrum width (95% C.I. 0.054, 0.146; P = 2x10^-5). …”

<i>Zip88E</i>^<i>Δ/Δ</i> larvae have decreased <i>MtnB</i>:<i>EYFP</i> expression. by Christopher D. Richards (4246669)

“…<p>A, B, D, E) <i>MtnB</i>:<i>EYFP</i> expression in third instar larval midguts from control and <i>Zip88E</i>^<i>Δ/Δ</i> homozygous larvae on basal medium (A and B) and after exposure to 2 mmol l^-1 ZnCl₂-supplemented medium (D, E). …”

Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

“…At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”

Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

“…At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”

The synchronous activity of SGN fiber populations is disrupted and their response to sound is decreased with increasing levels of <i>L</i>_<i>u</i> heterogeneity. by Maral Budak (6680351)

Interpretation of bidirectional MR. by Laurence J. Howe (5579186)

Tetrahydrohyperforin Inhibits the Proteolytic Processing of Amyloid Precursor Protein and Enhances Its Degradation by Atg5-Dependent Autophagy by Viviana A. Cavieres (500139)

“…We show herein that IDN5706 decreases the levels of ER degradation enhancer, mannosidase alpha-like 1 (EDEM1), a key chaperone related to endoplasmic-reticulum-associated degradation (ERAD). …”

Liability threshold model for nsCL/P. by Laurence J. Howe (5579186)

Supplementary Data from Increased frequency of travel in the presence of cross-immunity may act to decrease the chance of a global pandemic by R. N. Thompson (6480983)

Kif2a accumulation at the base of <i>Ttbk2</i>^{<i>sca11/gt</i>} cilia causes instability. by Emily Bowie (543704)

Table_2_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

“…<p>Mexico, one of the countries severely affected by COVID-19, accumulated more than 5. 1 all-cause excess deaths/1,000 inhabitants and 2.5 COVID-19 confirmed deaths/1,000 inhabitants, in 2 years. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

CAP256-VRC26 bnAbs display high activities at the pre- and post-CD4 attachment step. by Lucia Reh (546554)

Genetic information on 5 subjects carrying <i>NR5A1</i> mutations. by Jana Malikova (615672)

Subjects:

DataSheet_1_Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages.pdf by Cassandra L. R. van Doorn (11388245)